|Bid||3.8400 x 800|
|Ask||4.1000 x 1200|
|Day's Range||3.7300 - 4.0400|
|52 Week Range||2.7000 - 12.6000|
|Beta (3Y Monthly)||5.61|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 8, 2019 - May 13, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.00|
Celldex (CLDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Celldex Therapeutics, Inc. (CLDX) presented interim data from the Company’s CD40 agonist program in a late-breaking poster session today at the American Association for Cancer Research (AACR) Annual Meeting 2019. CD40, expressed on dendritic cells and other antigen presenting cells, is an important target for immunotherapy, as it plays a critical role in the activation of innate and adaptive immune responses.CDX-1140 is a fully human agonist anti-CD40 monoclonal antibody that was specifically designed to balance good systemic exposure and safety with potent biological activity, a profile which differentiates CDX-1140 from other CD40-activating antibodies.
Celldex Therapeutics, Inc. (CLDX) presented promising data from the Company’s growing bispecific and TAM (Tyro3, Axl, MerTK) receptor programs during poster sessions today at the American Association for Cancer Research (AACR) Annual Meeting 2019. “Our research and discovery efforts have yielded multiple promising candidates that address important needs in cancer immunotherapy and complement our pipeline,” said Tibor Keler, Ph.D., Executive Vice President and Chief Scientific Officer of Celldex Therapeutics. “CDX-527 joins two powerful pathways in the immune system, PD-1 blockade and CD27 costimulation.
The clinical-stage biotech stretched out its cash in the fourth quarter by cost reductions and took the necessary moves in the following months to retain its listing on the Nasdaq stock exchange.
HAMPTON, N.J., March 07, 2019 -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the fourth quarter and year ended December 31,.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on March 6) Chiasma Inc (NASDAQ: CHMA ) Magenta Therapeutics Inc ...
In the latest trading session, Celldex Therapeutics (CLDX) closed at $5.92, marking a -1.17% move from the previous day.
NEW YORK, Feb. 20, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
Celldex Therapeutics, Inc. (NASDAQ: CLDX) stock tanked Monday after the company effected a 15-to-1 reverse stock split that was first announced two days ago. The reverse split pushed Celldex’s share price from about 39 cents to about $5 per share, but the market’s negative initial reaction to the decision is typical of the response to reverse splits. Celldex was forced into the aggressive reverse split after the stock crashed 84 percent in the past year as the market lost its optimism about immunotherapy combination treatments.
HENDERSON, NV / ACCESSWIRE / February 11, 2019 / Investing in biotech companies can provide investors with huge gains. With that in mind, we're highlighting a few you should know about. One you should ...
Celldex Therapeutics, Inc. (CLDX) (“Celldex” or the “Company”) today announced that its Board of Directors has approved a one-for-fifteen reverse stock split of its common stock that became effective today upon the filing with the Secretary of the State of Delaware a Certificate of Amendment to its Certificate of Incorporation. Beginning on February 11, 2019, Celldex’s common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under the new CUSIP number 15117B202. As previously disclosed, at the Company’s Annual Meeting of Stockholders held on June 13, 2018, Celldex stockholders approved a proposal authorizing the Company’s Board of Directors to effect a reverse stock split by a ratio of not less than one-for-ten and not more than one-for-fifteen.
CORAL GABLES, FL / ACCESSWIRE / February 5, 2019 / The healthcare stock market has been a hotbed of excitement over the course of the past couple of years as companies across the healthcare industry have employed more nuanced approaches to how they offer care to patients. With the advent of new medical technologies and approaches to treating patients suffering from a myriad of diseases, news surrounding innovative companies putting their skills to the test in the healthcare industry has worked to attract investors looking for potential opportunities in the space. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Moleculin Biotech Inc (MBRX), Celldex Therapeutics Inc (CLDX), and Teladoc Health Inc (TDOC) represent four healthcare companies focused on innovating towards the future of healthcare.
HENDERSON, NV / ACCESSWIRE / February 5, 2019 / Some consider the small-cap and mid-cap - ''smid-cap'' - zone with market caps of $5 billion or less, a bit risky. They aren't wrong. However, if you can ...
CORAL GABLES, FL / ACCESSWIRE / February 4, 2019 / The future of the tech stock market will depend on two key factors: tech experts must continue to work to design and manufacture top-of-the-line products meant to elevate the human experience, and consumers must feel like these new pieces of tech will actually serve a significant purpose in their lives. ParcelPal Technology Inc (PTNYF) (PKG), Maxwell Technologies Inc (MXWL), Top Image Systems Ltd (TISA), and Celldex Therapeutics Inc (CLDX) represent four companies determined to utilize advanced technological solutions to improve the quality of life for consumers on a global scale. ParcelPal Technology Inc (PTNYF) (PKG), along with other companies in the space, is taking advantage of the fact that, as new technologies have been developed to meet the growing challenges in life, so too has the willingness of consumers to be persuadable, in terms of considering products they otherwise might not consider.
HENDERSON, NV / ACCESSWIRE / January 29, 2019 / Small cap securities in the biotechnology industry are always of interest to investors because several events can help increase the stock's share price at ...
HENDERSON, NV / ACCESSWIRE / January 23, 2019 / The market reached a level toward the end of last year where investors and analysts were throwing the "R" word (recession) around. The cause of ...
HENDERSON, NV / ACCESSWIRE / January 21, 2019 / Biotechnology companies have seen a ton of interest from Big Pharma so far in 2019. While it's not easy to project who may be next, there are several biotech ...